A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid
tumors.
Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult
subjects with advanced solid tumors.